The EBiSC team is working hard to implement improvements in how EBiSC operates. Due to some short-term disruption, please get in touch via if the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe.


SFC840-03-03 LRRK2-/-C11

Gene-edited iPSC line

Stock not immediately available - enquire for details
We are currently making some changes to how EBiSC operates and because of this there is a short period of time where orders cannot be placed.

If you are interested in accessing these cells, please contact EBiSC directly. For more information about the current transition process see here.
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to for countersignature. The EAUA must be fully signed before proceeding with your order.
To receive the Certificate of Analysis, please contact us.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.


Cell Line

hPSCreg name STBCi026-A-2
Alternative name(s)
SFC840-03-03 LRRK2-/-C11
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.


Depositor StemBANCC (STBC)

External Databases

hPSCreg STBCi026-A-2
BioSamples SAMEA5859480
Cellosaurus CVCL_A8Z9
Wikidata Q102114946

General Information

Publications View all related publications on hPSCreg (1)
This EBiSC line can be used for:
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of

Donor Information#

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA104493661

hIPSC Derivation#


The source cell information can be found in the parental cell line STBCi026-A.

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
Methods used

Vector free reprogramming


Derived under xeno-free conditions
Derived under GMP?
Available as clinical grade?

Culture Conditions#

The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
Passage method Enzyme-free cell dissociation
Medium mTeSR™ 1



Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Karyotype abnormalities compared to original iPSC line: small amplification in C14q and deletion in C19q
Karyotyping method: Molecular karyotyping by SNP array

Other Genotyping (Cell Line)

Genetic Modification#

Disease/phenotype related modifications
  • Parkinson disease
  • Parkinson's disease
  • paralysis agitans
Genetic modifications
LRRK2 (target)
Gene knock-out
CRISPR/Cas9-mediated disruption of exon 3 and clone-screening for bi-allelic out-of-frame repair, to create Lrrk2 knockout line.
CRISPR-associated (CRISPR/Cas) System